{
    "data": [
        {
            "title": "Safran and the Dalkia - Arverne Group Consortium Are Counting on Deep Geothermal Heat for a Low-carbon Industry",
            "description": "<div class=\"mdc-article-body\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Safran and the Dalkia - Arverne Group Consortium Are Counting on Deep Geothermal Heat for a Low-carbon Industry</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nRegulatory News:\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Safran Aircraft Engines, the world leader in aircraft propulsion, relies on the expertise of Dalkia, a subsidiary of EDF, and Arverne Drilling Services, a subsidiary of Arverne Group (Paris:ARVEN), to reach a new milestone in its low-carbon commitment. It becomes the first industrial player in the Paris region to install a deep geothermal power plant at its Villaroche site (Seine-et-Marne).</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nSafran Aircraft Engines has chosen the consortium to design, build and maintain its future geothermal power plant in Villaroche, one of its main production centers with over 5,000 employees. This unique facility, which will combine deep geothermal energy, heat pumps and modernized heating networks, will, at the end, replace 84% of the energy needs, currently supplied by gas boilers, with low-carbon, local and renewable energy.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nDrillings 1,650 meters deep, spaced one kilometer apart in the Dogger, where the water temperature reaches almost 75°C, will be carried out on the site, by the end of 2025. Commissioning of the geothermal power plant is scheduled for late 2026. By harnessing the heat of the subsoil, this solution will avoid the emission of 6,500 tonnes of CO2 per year, representing a 75% reduction in carbon emissions linked to heating the site.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThis pioneering project between Safran and the Dalkia-Arverne Drilling Services consortium is proof that industry can be both efficient and environmentally friendly and opens the way to new prospects for the decarbonization of industrial activities, which are essential to the country's economy.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Delphine Berilloux, Director of Human and Social Responsibility, in charge of Safran Aircraft Engines sites, says: </strong>“<em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">This strategic partnership fully reflects our commitment to a low-carbon industry. We are delighted to benefit from Dalkia-Arverne's proven expertise in deep geothermal energy, as we pursue our objective of reducing CO2 emissions from our industrial sites. This project is complementary to other major Safran initiatives, such as the installation of photovoltaic farms at some fifteen Group sites in France and abroad</em>.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n“<em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Through this partnership, Dalkia is demonstrating that solutions to reduce greenhouse gas emissions in industry do exist, and that geothermal energy is one of them. I salute the commitment of Safran Aircraft Engines which, through this ambitious and innovative project, will significantly reduce the carbon footprint of its site while strengthening its energy independence. It's an example that I'm convinced will be followed, especially since the potential is great in the Paris region</em>.” <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Sylvie Jéhanno, Chairman and CEO of Dalkia.</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">“This project bringing together leading French industrial players demonstrates the expertise of our companies and their shared commitment to decarbonizing industry through geothermal energy. We are proud that Safran Aircraft Engines has chosen our expertise to equip itself with a geothermal plant, which will provide renewable, local energy, enabling it to significantly reduce its carbon footprint. We are convinced that subsoil resources, and geothermal energy in particular, are essential levers for making a success of the energy transition and meeting the challenges of decarbonizing industry.” </em><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Pierre Brossollet, Founder, Chairman and CEO of Arverne Group.</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nSafran is an international high-technology group, operating in the aviation (propulsion, equipment and interiors), defense and space markets. Its core purpose is to contribute to a safer, more sustainable world, where air transport is more environmentally friendly, comfortable and accessible. Safran has a global presence, with 92 000 employees and sales of 23.2 billion euros in 2023, and holds, alone or in partnership, world or regional leadership positions in its core markets.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nSafran Aircraft Engines designs, produces and markets, alone or in partnership, civil and military aircraft engines offering the highest levels of performance, reliability and environmental protection. Through CFM International*, the company is the world leader in short- and medium-haul commercial aircraft propulsion.\n<br data-v-02ca9be7=\"\"/>*CFM International is a 50/50 joint venture between Safran Aircraft Engines and GE Aerospace.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nFor more information: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.safran-group.com&amp;esheet=54199925&amp;newsitemid=20250205484610&amp;lan=en-US&amp;anchor=www.safran-group.com&amp;index=1&amp;md5=8b960348b48dd875da8f0650326f49e1\" tabindex=\"0\">www.safran-group.com</a> and <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.safran-aircraft-engines.com&amp;esheet=54199925&amp;newsitemid=20250205484610&amp;lan=en-US&amp;anchor=www.safran-aircraft-engines.com&amp;index=2&amp;md5=050a8d8eadb5e43a281752d8e30de916\" tabindex=\"0\">www.safran-aircraft-engines.com</a> / @Safran and @SafranEngines on X.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nDalkia: taking up the climate challenge together! For 85 years, Dalkia, a subsidiary of the EDF Group and a leader in energy services, has been investing in and developing renewable and recovered energies, and supporting its customers over the long term to help them save energy and reduce their CO2 emissions. More than 20,000 employees throughout France and abroad maintain and operate facilities for industrial sites, commercial buildings, local authorities, healthcare establishments and housing, using innovative, high-performance solutions to accelerate the decarbonization of sites and regions. Find out more about our solutions on our eco-responsible website <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dalkia.fr&amp;esheet=54199925&amp;newsitemid=20250205484610&amp;lan=en-US&amp;anchor=www.dalkia.fr&amp;index=3&amp;md5=b5b515d728df973f4c1a447ad0522790\" tabindex=\"0\">www.dalkia.fr</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nArverne Group specializes in harnessing underground resources to transform them into environmentally friendly, local and renewable energy, contributing to the prosperity of local communities. As an integrated industrial player, Arverne Group spans the entire underground value chain, from exploration to drilling and production to sales to end-users. Arverne Group aims to become the French leader in geothermal energy and its by-products, including low-carbon geothermal lithium.\n<br data-v-02ca9be7=\"\"/>Founded in Pau in 2018, Arverne Group has structured its business activities around several subsidiaries, notably 2gré (sale of geothermal heat), Lithium de France (geothermal heat and extraction and sale of geothermal lithium) and Arverne Drilling Services (drilling operations).\n<br data-v-02ca9be7=\"\"/>A mission-driven company, Arverne Group is listed on the Tech Leaders segment of Euronext Paris (ISIN FR001400JWR8, symbol ARVEN).\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.arverne.earth&amp;esheet=54199925&amp;newsitemid=20250205484610&amp;lan=en-US&amp;anchor=www.arverne.earth&amp;index=4&amp;md5=33d92ecff67962b1997057dad47f6962\" tabindex=\"0\">www.arverne.earth</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205484610r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en\"/></source></source></source></picture></span><span data-v-02ca9be7=\"\"></span></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Media relations :</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Dalkia</strong> : Alice PARENTI\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:alice.parenti@dalkia.fr\" tabindex=\"0\">alice.parenti@dalkia.fr</a> / +33625573404\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Arverne Group :</strong> Frédérique BARTHELEMY\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:Frederique.barthelemy@arverne.earth\" tabindex=\"0\">Frederique.barthelemy@arverne.earth</a> / +33615809772\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">View source version on businesswire.com: </span><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.businesswire.com/news/home/20250205484610/en/\" tabindex=\"0\">https://www.businesswire.com/news/home/20250205484610/en/</a></span></p></div>",
            "pub_date": "2025-02-05 16:20:46",
            "link": "https://www.morningstar.com/news/business-wire/20250205484610/safran-and-the-dalkia-arverne-group-consortium-are-counting-on-deep-geothermal-heat-for-a-low-carbon-industry",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SASOL LIMITED: TRADING STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 2024",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nSASOL LIMITED: TRADING STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 2024\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">SASOL LIMITED: TRADING STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 2024</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">JOHANNESBURG, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">JOHANNESBURG</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- In terms of paragraph 3.4(b)(i) of the Listing Requirements of the JSE Limited (JSE), a company listed on the JSE is required to publish a Trading statement as soon as it is satisfied that a reasonable degree of certainty exists that the financial results for the next period to be reported on, will differ by at least 20% from the financial result for the previous corresponding period.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Accordingly, stakeholders are advised that, for the six months ended <span data-v-02ca9be7=\"\">31 December 2025</span>:</p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Adjusted earnings before interest, tax, depreciation and amortisation (adjusted EBITDA*) is expected to be between R22 billion and R25 billion compared to the prior half year adjusted EBITDA of R28 billion, representing a decrease of between 11% and 22%;</li><li data-v-6f730619=\"\">Earnings per share (EPS) are expected to be between R6,00 and R8,00 compared to the prior half year EPS of R15,19 (representing a decrease of between 47% and 61%); and</li><li data-v-6f730619=\"\">Headline earnings per share (HEPS) are expected to be between R13,00 and R15,00 compared to the prior half year HEPS of R20,37 (representing a decrease of between 26% and 36%); and</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The decrease in earnings in the period is primarily due to:</p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">A 13% decline in the average Rand per barrel of Brent Crude Oil price and a significant decline in refining margins and fuel price differentials;</li><li data-v-6f730619=\"\">­A 5% decrease in sales volumes associated with lower production and/or lower market demand as detailed in the Production and Sales Metrics published on <span data-v-6f730619=\"\">23 January 2025</span>, which can be found on our website: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.sasol.com/sasol-sens/production-and-sales-metrics-six-months-ended-31-december-2024\" tabindex=\"0\">https://www.sasol.com/sasol-sens/production-and-sales-metrics-six-months-ended-31-december-2024</a>;</li><li data-v-6f730619=\"\">Notable non-cash adjustments (before taxation) including:<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">A net loss of R6,2 billion from remeasurement items compared to a net loss of R5,8 billion in the prior half year, mainly due to the Secunda and Sasolburg liquid fuels refinery cash generating units remaining fully impaired. The full amount of costs capitalised during the current period of R5,6 billion are impaired;</li><li data-v-6f730619=\"\">Unrealised losses of R0,1 billion on the translation of monetary assets and liabilities, and valuation of financial instruments and derivative contracts compared to unrealised gains of R2,7 billion in the prior half year.</li></ul></li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">These negative financial impacts were partially offset by an increase in average chemicals basket prices, stringent cost management and efficient capital expenditure.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The financial information underpinning this trading statement has not been reviewed and reported on by the Company's external auditors.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Sasol remains focused on improving the performance of the business and will present its 2025 interim financial results, including more detail on improvement plans, on Monday, <span data-v-02ca9be7=\"\">24 February 2025</span> at 09h00 (SA time). This will be followed by a market call, hosted by President and Chief Executive Officer, <span data-v-02ca9be7=\"\">Simon Baloyi</span>, and Chief Financial Officer, <span data-v-02ca9be7=\"\">Walt Bruns</span>, to address questions.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Please connect to the call via the webcast link: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.corpcam.com/Sasol24022025\" tabindex=\"0\">https://www.corpcam.com/Sasol24022025</a> or via teleconference call link: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=8853546&amp;linkSecurityString=26eaaf0156\" tabindex=\"0\">https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=8853546&amp;linkSecurityString=26eaaf0156</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">* Adjusted EBITDA is calculated by adjusting operating profit for depreciation, amortisation, share-based payments, remeasurement items, change in discount rates of our rehabilitation provisions, all unrealised translation gains and losses, and all unrealised gains and losses on our derivatives and hedging activities.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Adjusted EBITDA is not a defined term under International Financial Reporting Standards and may not be comparable with similarly titled measures reported by other companies. The aforementioned adjustments are the responsibility of the directors of Sasol. The adjustments have been prepared for illustrative purposes only and due to their nature, may not fairly present Sasol´s financial position, changes in equity, results of operations or cash flows.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">For further information, please contact:</strong><br data-v-02ca9be7=\"\"/>Sasol Investor Relations,<br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">Tiffany Sydow</span>, VP Investor Relations<br data-v-02ca9be7=\"\"/>Telephone: +27 (0) 71 673 1929<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:investor.relations@sasol.com\" tabindex=\"0\">investor.relations@sasol.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Disclaimer - Forward-looking statements</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Sasol may, in this document, make certain statements that are not historical facts and relate to analyses and other information which are based on forecasts of future results and estimates of amounts not yet determinable. These statements may also relate to our future prospects, expectations, developments, and business strategies. Examples of such forward-looking statements include, but are not limited to, the capital cost of our projects and the timing of project milestones; our ability to obtain financing to meet the funding requirements of our capital investment programme, as well as to fund our ongoing business activities and to pay dividends; statements regarding our future results of operations and financial condition, and regarding future economic performance including cost containment, cash conservation programmes and business optimisation initiatives; recent and proposed accounting pronouncements and their impact on our future results of operations and financial condition; our business strategy, performance outlook, plans, objectives or goals; statements regarding future competition, volume growth and changes in market share in the industries and markets for our products; our existing or anticipated investments, acquisitions of new businesses or the disposal of existing businesses, including estimates or projection of internal rates of return and future profitability; our estimated oil, gas and coal reserves; the probable future outcome of litigation, legislative, regulatory and fiscal developments, including statements regarding our ability to comply with future laws and regulations; future fluctuations in refining margins and crude oil, natural gas and petroleum and chemical product prices; the demand, pricing and cyclicality of oil, gas and petrochemical product prices; changes in the fuel and gas pricing mechanisms in <span data-v-02ca9be7=\"\">South Africa</span> and their effects on prices, our operating results and profitability; statements regarding future fluctuations in exchange and interest rates and changes in credit ratings; total shareholder return; our current or future products and anticipated customer demand for these products; assumptions relating to macroeconomics; climate change impacts and our climate change strategies, our development of sustainability within our businesses, our energy efficiency improvement, carbon and greenhouse gas emission reduction targets, our net zero carbon emissions ambition and future low-carbon initiatives, including relating to green hydrogen and sustainable aviation fuel; our estimated carbon tax liability; cyber security; and statements of assumptions underlying such statements. Words such as \"believe\", \"anticipate\", \"expect\", \"intend\", \"seek\", \"will\", \"plan\", \"could\", \"may\", \"endeavour\", \"target\", \"forecast\" and \"project\" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections, and other forward-looking statements will not be achieved. If one or more of these risks materialise, or should underlying assumptions prove incorrect, our actual results may differ materially from those anticipated. You should understand that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. These factors and others are discussed more fully in our most recent annual report on Form 20-F filed on <span data-v-02ca9be7=\"\">6 September 2024</span> and in other filings with the United States Securities and Exchange Commission. The list of factors discussed therein is not exhaustive; when relying on forward-looking statements to make investment decisions, you should carefully consider foregoing factors and other uncertainties and events, and you should not place undue reliance on forward-looking statements. Forward-looking statements apply only as of the date on which they are made, and we do not undertake any obligation to update or revise any of them, whether as a result of new information, future events or otherwise.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=IO12265&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/sasol-limited-trading-statement-for-the-six-months-ended-31-december-2024-302368590.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/sasol-limited-trading-statement-for-the-six-months-ended-31-december-2024-302368590.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Sasol Limited</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 16:20:45",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205io12265/sasol-limited-trading-statement-for-the-six-months-ended-31-december-2024",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Clarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nClarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">Clarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">LONDON, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Software-as-a-Service, cloud-based library services and discovery platform to be implemented in nine universities and 82 academic and research libraries across <span data-v-370fea16=\"\">Croatia</span></em></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">LONDON</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=4011963572&amp;u=https%3A%2F%2Fclarivate.com%2F&amp;a=Clarivate+Plc\" tabindex=\"0\">Clarivate Plc</a> (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that the National and University Library in <span data-v-02ca9be7=\"\">Zagreb</span> has selected Clarivate to provide its unified library services and discovery platform.</p>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.html\" tabindex=\"0\">\n<span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 1x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 2x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 1x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 2x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 1x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 2x,https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg\"/></source></source></source></picture></span>\n</a>\n</p>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The National and University Library in <span data-v-02ca9be7=\"\">Zagreb</span> (NSK) is <span data-v-02ca9be7=\"\">Croatia's</span> leading cultural and research institution, serving as both the National Library of <span data-v-02ca9be7=\"\">Croatia</span> and the University of <span data-v-02ca9be7=\"\">Zagreb's</span> main library. Its mission is to develop collections and services that promote <span data-v-02ca9be7=\"\">Croatia's</span> cultural and scientific heritage as well as to build a Croatian national library system.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The NSK will implement <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=3006744924&amp;u=https%3A%2F%2Fexlibrisgroup.com%2Fproducts%2Falma-library-services-platform%2F%3Fcampaignname%3DPR_LeadGen_AG_XBU_Global%26campaignid%3D701QO00000QviLVYAZ%26utm_campaign%3DPR_LeadGen_AG_XBU_Global%26utm_source%3DPress_Release%26utm_medium%3DEarned_Press%26utm_content%3D%26utm_term%3D&amp;a=Ex+Libris+Alma\" tabindex=\"0\">Ex Libris Alma</a> and <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=3723195327&amp;u=https%3A%2F%2Fexlibrisgroup.com%2Fproducts%2Fprimo-discovery-service%2F%3Fcampaignname%3DPR_LeadGen_AG_XBU_Global%26campaignid%3D701QO00000QviLVYAZ%26utm_campaign%3DPR_LeadGen_AG_XBU_Global%26utm_source%3DPress_Release%26utm_medium%3DEarned_Press%26utm_content%3D%26utm_term%3D&amp;a=Ex+Libris+Primo\" tabindex=\"0\">Ex Libris Primo</a> from Clarivate to build a modern, unified library system, streamlining the existing infrastructure of multiple library systems and data formats. The NSK will lead the new solution for the academic and research library system across the country, totaling nine universities and 82 libraries, with a cloud-based subscription service.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Professor Stričević, Director General, NSK said: \"I am pleased that the National and University Library selected Alma and Primo as a unified solution that will foster the process of digital transformation of the university library system in <span data-v-02ca9be7=\"\">Croatia</span> with the National and University Library at the forefront. The activity is realized as part of the<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4354970-1&amp;h=3750775116&amp;u=https%3A%2F%2Fwww.carnet.hr%2Fen%2Fprojekt%2Fe-universities%2F&amp;a=+e-Universities+project\" tabindex=\"0\"> e-Universities project</a> and financed from the National Recovery and Resilience Plan 2021 – 2026.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Dr <span data-v-02ca9be7=\"\">Dijana Machala</span>, Assistant Director, University Library Affairs, NSK, who is leading this national strategic project said: \"We are excited to start the implementation of Alma Network Zone for NSK and 82 academic and research libraries in <span data-v-02ca9be7=\"\">Croatia</span>. NSK selected Alma and Primo with the aim to provide a resilient library digital infrastructure that will empower learning and research.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Yariv Kursh</span>, Senior Vice President and General Manager, Ex Libris and Innovative, part of Clarivate said: \"At Clarivate, we are dedicated to providing forward thinking solutions that support the missions of national libraries such as the National and University Library in <span data-v-02ca9be7=\"\">Zagreb</span>. Today's announcement is yet another example of our national-level collaboration with libraries and is testament to how we support and empower them through transformational change. Our collaboration will foster learning and discovery for future generations and make <span data-v-02ca9be7=\"\">Croatia's</span> rich heritage accessible to researchers, scholars and the public.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Clarivate</strong><br data-v-02ca9be7=\"\"/>Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights &amp; analytics, workflow solutions and expert services in the areas of Academia &amp; Government, Intellectual Property and Life Sciences &amp; Healthcare. For more information, please visit www.clarivate.com</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY11283&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content to download multimedia:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/clarivate-selected-by-national-and-university-library-in-zagreb-croatia-to-create-a-unified-national-library-platform-302367687.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/clarivate-selected-by-national-and-university-library-in-zagreb-croatia-to-create-a-unified-national-library-platform-302367687.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Clarivate Plc</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 16:15:46",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny11283/clarivate-selected-by-national-and-university-library-in-zagreb-croatia-to-create-a-unified-national-library-platform",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences",
            "description": "<div class=\"mdc-article-body\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nAfrica’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding today, on the sidelines of the 2nd Vaccine and Other Health Products Manufacturing Forum for African Union Member States, organized by Africa CDC and hosted by the Egyptian United Procurement Authority (UPA) in Cairo. This collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines for both human and animal health.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThe platform, taking place in Egypt, will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify<span data-v-02ca9be7=\"\">®</span> mRNA synthesis and Ncapsulate<span data-v-02ca9be7=\"\">®</span> formulation technologies, combined with EVA Pharma’s vaccine development, top notch GMP sterile manufacturing expertise and commercialization capabilities. The collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations. The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration will focus on developing next generation saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases at their source.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThis initiative will contribute to achieve Africa CDC’s target of 60% local vaccine production by 2040 and Egypt’s ambitious goal to manufacture 385 million vaccine doses annually by 2030, establishing itself as a global leader in vaccine production. It also supports public health resilience and food security across Africa and the Middle East.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n“This moment will reshape African and global health security as we know it,” said Dr. Riad Armanious, CEO of EVA Pharma, expressing his enthusiasm. “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks. This is not tomorrow’s promise, it is today’s reality: with an operational biologics manufacturing site producing 100 million vials and 1.5 billion doses of animal health vaccine already commercialized, we have the infrastructure to streamline vaccine production using groundbreaking mRNA technology and ensuring unparalleled safety.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nAccording to Marc Montserrat, CEO of DNA Script,\n<br data-v-02ca9be7=\"\"/>“Our collaboration with EVA Pharma and Univercells-Quantoom to implement our proprietary enzymatic DNA synthesis technology directly supports the mission to accelerate vaccine development and delivery worldwide, and more broadly aligns with our vision to make biology programmable. By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we're helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nJosé Castillo, CEO of Quantoom Biosciences, added: “This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-saving vaccines and therapeutics accessible to underserved populations.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nHala Audi, CEO of Unizima, echoed this sentiment: “EVA Pharma is already showing the world the power of investing in the biopharma sector to create health and wealth in Africa and the Middle East. We are proud to support the tech transfer of some of the best technology for DNA and RNA manufacturing to Egypt, as the next chapter in their growth.”\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThis MoU reflects a strong commitment to advance global health equity and foster sustainable biopharma development. By combining their strengths, the partners aim to deliver versatile, scalable, and impactful solutions. These will shape the future of healthcare in Egypt and beyond, while contributing to economic resilience and regional pandemic preparedness and response.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About EVA Pharma</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nEVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nWith a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nGuided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nEVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nFor more information, please visit: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evapharma.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.evapharma.com&amp;index=1&amp;md5=4ccca5070f64fbdb80c1824ab69c3198\" tabindex=\"0\">www.evapharma.com</a> &amp; <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evapharma.com%2Fnewsroom&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.evapharma.com%2Fnewsroom&amp;index=2&amp;md5=38b2d3ad65988ac7f4ab0768ff8b986e\" tabindex=\"0\">https://www.evapharma.com/newsroom</a> or follow us on <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FEvapharma%2F&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=b86c806045f1d5aac14daa6a02e2cc06\" tabindex=\"0\">Facebook</a>, <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Feva-pharma%2F&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=a265adc842d0e2e0e8e084110d25569b\" tabindex=\"0\">LinkedIn</a> &amp; <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Feva.pharma%2F&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=85de8f0ad98613fa5c359bc4c43067ec\" tabindex=\"0\">Instagram</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About EVA Pharma’s mRNA Innovation Hub</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nEVA Pharma has notably focused on localizing innovation in recent years through investing in research infrastructure and financing. The company has established an in-house research and development footprint, including its mRNA Innovation Hub, which is fully equipped to handle the complete mRNA vaccine development lifecycle—from digital sequencing to final drug formulation. This includes antigen selection, protein engineering, mRNA construct design, process development, innovative formulation delivery systems, and analytical method development.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About DNA Script</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nDNA Script is at the forefront of transforming biological research through advanced enzymatic DNA synthesis technology. We provide pioneering solutions for DNA production, including our cutting-edge SYNTAX<span data-v-02ca9be7=\"\">®</span> DNA printer and our enzymatic synthesis technology that enables the production of longer and more complex DNA sequences. Our innovations are driving progress across critical scientific domains, including mRNA vaccine development, cell and gene therapy, and broader biomolecular research. By offering researchers unprecedented capabilities to synthesize high-quality DNA sequences, we are accelerating discoveries that have the potential to revolutionize healthcare, biotechnology, and scientific understanding. More info: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dnascript.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.dnascript.com&amp;index=6&amp;md5=6c084f6b9bcfb4c0b40a49b3bc0c0719\" tabindex=\"0\">www.dnascript.com</a>.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Quantoom Biosciences</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nQuantoom Biosciences is leading the revolution in mRNA- and saRNA-based vaccines and therapeutics by providing turnkey solutions for (sa)mRNA &amp; LNP manufacturing. Its cutting-edge Ntensify<span data-v-02ca9be7=\"\">®</span> technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&amp;D to commercial manufacturing. Launched in 2023, Ntensify has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate<span data-v-02ca9be7=\"\">®</span> technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based drugs. Located in Belgium, Quantoom Biosciences thrives in a dynamic biotech ecosystem, driving innovation in mRNA production to make life-changing therapies available to everyone, everywhere. More info : <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quantoom.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.quantoom.com&amp;index=7&amp;md5=4dad06f6fa8e331fad48dad8982a3d29\" tabindex=\"0\">www.quantoom.com</a>.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">About Unizima</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nUnizima is a trusted consultancy specialized in public and private partnerships for establishing bioproduction facilities and develop the workforce in emerging biotech ecosystems. As a partner to biopharma manufacturers, governments, and global health agencies, Unizima enables the sustainable production of biologics—including vaccines, monoclonal antibodies, and recombinant protein. From project inception to technology transfer and training, Unizima integrates all necessary elements to bring biomanufacturing initiatives to life. More info: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.unizima.com&amp;esheet=54199706&amp;newsitemid=20250205825293&amp;lan=en-US&amp;anchor=www.unizima.com&amp;index=8&amp;md5=e04881b9c5dbabcc523afc3a2652d46a\" tabindex=\"0\">www.unizima.com</a>.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Disclosure Statement</strong>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\nThe contents of this announcement include statements that are, or may be deemed to be, \"forward-looking statements\". These forward-looking statements can be identified using forward-looking terminology, including the words \"believes\", \"estimates,\" \"anticipates\", \"expects\", \"intends\", \"may\", \"will\", \"plans\", \"continue\", \"ongoing\", \"potential\", \"predict\", \"project\", \"target\", \"seek\" or \"should\", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 1x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 2x,https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250205825293r1&amp;sid=mstr3&amp;distro=nx&amp;lang=en\"/></source></source></source></picture></span><span data-v-02ca9be7=\"\"></span></p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">EVA Pharma \n</strong><br data-v-02ca9be7=\"\"/>Marina Mansour\n<br data-v-02ca9be7=\"\"/>Corporate communications Professional\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:Marina.mansour@evapharma.com\" tabindex=\"0\">Marina.mansour@evapharma.com</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">DNA Script \n</strong><br data-v-02ca9be7=\"\"/>Rachel Macmaster, PhD\n<br data-v-02ca9be7=\"\"/>Director, Global Marketing\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:publicrelations@dnascript.co\" tabindex=\"0\">publicrelations@dnascript.co</a>\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n<strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Quantoom Biosciences / Unizima \n</strong><br data-v-02ca9be7=\"\"/>Jonathan Lecocq\n<br data-v-02ca9be7=\"\"/>MarCom Manager\n<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:j.lecocq@quantoom.com\" tabindex=\"0\">j.lecocq@quantoom.com \n</a><br data-v-02ca9be7=\"\"/>+32 476 81 12 44\n\n</p><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">View source version on businesswire.com: </span><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.businesswire.com/news/home/20250205825293/en/\" tabindex=\"0\">https://www.businesswire.com/news/home/20250205825293/en/</a></span></p></div>",
            "pub_date": "2025-02-05 16:15:45",
            "link": "https://www.morningstar.com/news/business-wire/20250205825293/africa-and-europe-join-forces-to-revolutionize-rna-based-vaccines-and-therapeutics-production-mou-signed-between-eva-pharma-dna-script-quantoom-biosciences",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Ericsson appoints Charlotte Levert as Chief People Officer",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nEricsson appoints Charlotte Levert as Chief People Officer\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">Ericsson appoints Charlotte Levert as Chief People Officer</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">STOCKHOLM, Feb. 5, 2025</p></span>\n<span>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Effective as of <span data-v-6f730619=\"\">February 10, 2025</span></li><li data-v-6f730619=\"\">Becomes member of Ericsson's Executive Team, reporting to the CEO</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">STOCKHOLM</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- Ericsson (NASDAQ: ERIC) today announces the appointment of <span data-v-02ca9be7=\"\">Charlotte Levert</span> as its new Chief People Officer, Senior Vice President, and Head of Group Function People. <span data-v-02ca9be7=\"\">Charlotte Levert</span> who is currently Vice President and Head of People Business Area Cloud and Software Services will replace <span data-v-02ca9be7=\"\">MajBritt Arfert</span>, whose departure Ericsson announced in <span data-v-02ca9be7=\"\">October 2024</span>. <span data-v-02ca9be7=\"\">Charlotte Levert</span> will take up her new position on <span data-v-02ca9be7=\"\">February 10</span> and will be based in <span data-v-02ca9be7=\"\">Sweden</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Charlotte Levert</span> has held executive positions within Ericsson across several business areas. She has most recently held the position of Head of People Business Area Managed Services. Before joining Ericsson, <span data-v-02ca9be7=\"\">Charlotte Levert</span> was Head of HR Sweden &amp; Global HR business partner at Tieto and has held various senior management positions within human resources. She holds a Bachelor in Business Management &amp; Human Resources.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Börje Ekholm, President and CEO of Ericsson, says: \"Charlotte will be an integral part as we are entering the next chapter of Ericsson's strategy and in the continued evolution of the People agenda. She brings a strong track record from different organizations including different parts of Ericsson and I'm very much looking forward to having Charlotte join the Executive Team.\"</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Commenting on the appointment, <span data-v-02ca9be7=\"\">Charlotte Levert</span> says: \"I am truly honored to take on this role and grateful for the trust. Working at Ericsson means we all get the chance to be part of shaping the future. I am looking forward to co-creating a future-proof organization and where Ericsson remains a great place to work.\"  </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In <span data-v-02ca9be7=\"\">October 2024</span> Ericsson announced that <span data-v-02ca9be7=\"\">MajBritt Arfert</span> would step down after having been with Ericsson for over 38 years and a member of the Company's Executive Team since the autumn of 2016. <span data-v-02ca9be7=\"\">MajBritt Arfert</span> will be available for Ericsson during the spring and leave Ericsson at the end of <span data-v-02ca9be7=\"\">May 2025</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">NOTES TO EDITORS:</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">FOLLOW US:</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Subscribe to Ericsson press releases <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=1079130181&amp;u=https%3A%2F%2Fwww.ericsson.com%2Fen%2Fnewsroom%2Flatest-news%2Fpress-subscription&amp;a=here\" tabindex=\"0\">here</a><br data-v-02ca9be7=\"\"/>Subscribe to Ericsson blog posts <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2221444276&amp;u=https%3A%2F%2Fforyou.ericsson.com%2Fblog-subscription-center.html&amp;a=here\" tabindex=\"0\">here</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2037278625&amp;u=https%3A%2F%2Ftwitter.com%2Fericsson&amp;a=https%3A%2F%2Ftwitter.com%2Fericsson\" tabindex=\"0\">https://twitter.com/ericsson</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2291013006&amp;u=https%3A%2F%2Fwww.facebook.com%2Fericsson&amp;a=https%3A%2F%2Fwww.facebook.com%2Fericsson\" tabindex=\"0\">https://www.facebook.com/ericsson</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2256695802&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fericsson&amp;a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fericsson\" tabindex=\"0\">https://www.linkedin.com/company/ericsson</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">MORE INFORMATION AT:<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=3336389815&amp;u=https%3A%2F%2Fwww.ericsson.com%2Fen%2Fnewsroom&amp;a=Ericsson+Newsroom\" tabindex=\"0\">Ericsson Newsroom</a><br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:media.relations@ericsson.com\" tabindex=\"0\">media.relations@ericsson.com</a>  (+46 10 719 69 92)<br data-v-02ca9be7=\"\"/><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:investor.relations@ericsson.com\" tabindex=\"0\">investor.relations@ericsson.com</a>  (+46 10 719 00 00)</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">ABOUT ERICSSON:<br data-v-02ca9be7=\"\"/>Ericsson's high-performing networks provide connectivity for billions of people every day. For nearly 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=2440795883&amp;u=http%3A%2F%2Fwww.ericsson.com%2F&amp;a=www.ericsson.com\" tabindex=\"0\">www.ericsson.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information was brought to you by Cision <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=3538047915&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" tabindex=\"0\">http://news.cision.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=83647445&amp;u=https%3A%2F%2Fnews.cision.com%2Fericsson%2Fr%2Fericsson-appoints-charlotte-levert-as-chief-people-officer%2Cc4100082&amp;a=https%3A%2F%2Fnews.cision.com%2Fericsson%2Fr%2Fericsson-appoints-charlotte-levert-as-chief-people-officer%2Cc4100082\" tabindex=\"0\">https://news.cision.com/ericsson/r/ericsson-appoints-charlotte-levert-as-chief-people-officer,c4100082</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The following files are available for download:</p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355884-1&amp;h=4280032145&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F15448%2F4100082%2F3244109.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F15448%2F4100082%2F3244109.pdf\" tabindex=\"0\">https://mb.cision.com/Main/15448/4100082/3244109.pdf</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Ericsson appoints Charlotte Levert as Chief People Officer</span></p>\n</td></tr></tbody></table></span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY12275&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/ericsson-appoints-charlotte-levert-as-chief-people-officer-302368573.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/ericsson-appoints-charlotte-levert-as-chief-people-officer-302368573.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Ericsson</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 16:05:45",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny12275/ericsson-appoints-charlotte-levert-as-chief-people-officer",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "ASSA ABLOY: Quarterly Report Q4 2024",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nASSA ABLOY: Quarterly Report Q4 2024\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">ASSA ABLOY: Quarterly Report Q4 2024</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">STOCKHOLM, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">STOCKHOLM</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ --</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Margin target reached for year 2024</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Fourth quarter</strong>         </p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Net sales increased by 7% to <span data-v-6f730619=\"\">SEK 39,575 M</span> (36,970), with organic growth of 0% (0) and acquired net growth of 6% (11). Exchange rates affected sales by 1% (1).           </li><li data-v-6f730619=\"\">Organic sales growth was strong in Global Technologies, good in Americas, stable in EMEIA, while organic sales declined in Entrance Systems and declined significantly in Asia Pacific.           </li><li data-v-6f730619=\"\">Eight acquisitions with combined annual sales of more than <span data-v-6f730619=\"\">SEK 1 bn</span> were completed in the quarter.           </li><li data-v-6f730619=\"\">Operating income<span data-v-6f730619=\"\">1</span> (EBITA) increased by 15% to a record <span data-v-6f730619=\"\">SEK 6,898 M</span> (6,008) with an operating margin of 17.4% (16.2).        </li><li data-v-6f730619=\"\">Operating income<span data-v-6f730619=\"\">1</span> (EBIT) increased by 14% and amounted to a record of <span data-v-6f730619=\"\">SEK 6,529 M</span> (5,722), with an operating margin of 16.5% (15.5).   </li><li data-v-6f730619=\"\">Net income<span data-v-6f730619=\"\">1 </span>amounted to a record <span data-v-6f730619=\"\">SEK 4,214 M</span> (3,969).        </li><li data-v-6f730619=\"\">Earnings per share<span data-v-6f730619=\"\">1</span> amounted to <span data-v-6f730619=\"\">SEK 3.81</span> (3.56).        </li><li data-v-6f730619=\"\">Record operating cash flow of <span data-v-6f730619=\"\">SEK 8,010 M</span> (7,315).         </li><li data-v-6f730619=\"\">The Board of Directors proposes a dividend of <span data-v-6f730619=\"\">SEK 5.90</span> (5.40) per share for 2024, to be distributed in two equal installments.</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Sales and income</strong></p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Fourth quarter</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">January-December</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2023</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2024</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Δ</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2023</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">2024</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Δ</strong></span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Sales, SEK M</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">36,970</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">39,575</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">140,716</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">150,162</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7 %</strong></span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Of which:</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Organic growth</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">133</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–112 </span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">0 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">3,393</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–1,132 </span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–1%</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Acquisitions and divestments</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">3,572</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">2,215</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">6 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">10,651</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">11,326</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">8 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Exchange rate effects</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">349</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">502</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">1 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">5,879</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–748 </span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">0 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Operating income (EBIT)</strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><span data-v-43363f62=\"\"><span data-v-43363f62=\"\">1</span></span></strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">, SEK M</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">5,722</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">6,529</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">14 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">22,185</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">24,296</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">10 %</strong></span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Operating margin (EBITA)<span data-v-02ca9be7=\"\">1</span>, %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">16.2 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">17.4 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">16.5 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">17.1 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Operating margin (EBIT)</strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><span data-v-43363f62=\"\"><span data-v-43363f62=\"\">1</span></span></strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">, %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">15.5 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">16.5 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">15.8 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">16.2 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Income before tax<span data-v-02ca9be7=\"\">1</span>, SEK M</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">4,879</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">5,684</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">16 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">19,654</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">20,914</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">6 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Net income<span data-v-02ca9be7=\"\">1</span>, SEK M</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">3,969</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">4,214</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">6 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">15,049</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">15,636</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">4 %</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Operating cash flow, SEK M</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">7,315</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">8,010</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">10 %</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">25,232</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">23,052</span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">–9%</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Earnings per share</strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\"><span data-v-43363f62=\"\"><span data-v-43363f62=\"\">1</span></span></strong><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">, SEK</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">3.56</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">3.81</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">7 %</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">13.54</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">14.09</strong></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">4 %</strong></span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">1 </span>Excluding items affecting comparability. Please see the section \"Items affecting comparability\" in the report for further details about the financial effects in 2024. For information about items affecting comparability in 2023, please see the Year-end report 2023, available at assaabloy.com.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Comments by the President and CEO</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Margin target reached for year 2024</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">As we close 2024, I am proud to share that ASSA ABLOY showed resilience and agility in a mixed market environment, concluding the year with solid performance. For the full year, sales grew by 7%, reflecting strong contribution from acquisitions of 8%, and a small organic sales decline of 1%. Our operating margin expanded to 16.2%, within the target range of 16-17%.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">In the fourth quarter of 2024, organic sales were stable, with net positive contribution from acquisitions of 6% and currency effects of 1%. Global Technologies delivered strong organic growth of 5% with strong performance in most business areas and with Physical Access Control having comparable figures at normalized levels for the full quarter. Americas delivered good organic growth of 2%, with strong growth in the North America Non-Residential segment and in <span data-v-02ca9be7=\"\">Latin America</span>. Organic sales were stable in EMEIA with commercial segments compensating for continued weak residential demand. Similarly, weak residential markets and weak demand for loading docks resulted in an organic sales decline of 2% in Entrance Systems. <span data-v-02ca9be7=\"\">Asia Pacific's</span> organic sales declined significantly by 11%, mainly due to very weak demand in <span data-v-02ca9be7=\"\">China</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The operating profit for the quarter increased by 14% to a record <span data-v-02ca9be7=\"\">SEK 6,529 M</span> with a corresponding margin of 16.5% (15.5). The operating leverage was very strong at 120 bps, driven by continued price/cost tailwind and strong operational execution, overcompensating for dilution from acquisitions. The operating cash flow increased by 10% in the quarter to a record <span data-v-02ca9be7=\"\">SEK 8,010 M</span> with a cash conversion of 141% (150).</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Focus on accelerating our sales growth</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Accelerating organic growth remains a key priority going forward. An important part of our strategy is upgrading the installed base with innovative digital and electromechanical products and solutions. We invest 4% of annual sales in R&amp;D which allows us to strengthen our offering and drive the transition forward. Electromechanical products and solutions are the most important growth driver in our portfolio, with currency adjusted growth of 8% in 2024 and an annual growth rate of 9% in the last ten years in our regional divisions. Through upgrades we can support customers with enhanced security and convenience, but also grow recurring revenue streams. Recurring revenue continues to be a key driver for growth with subscription-based models, service agreements, and digital solutions like remote monitoring and mobile access. In 2024, sales of our subscription-based solutions grew by 18%. Our <span data-v-02ca9be7=\"\">decentralized</span> organization and region-specific product development provide further opportunities in the emerging markets, that only represent 13% of our sales. In 2024, our currency adjusted sales in emerging markets excluding <span data-v-02ca9be7=\"\">China</span> grew by 10%.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">A record 26 acquisitions were completed in 2024, adding annualized sales close to <span data-v-02ca9be7=\"\">SEK 8 bn</span>. In the fourth quarter, we completed eight acquisitions. Acquisitions remain a key driver for growth and the pipeline remains strong.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">By leveraging our market-leading products and solutions with our local knowledge and global presence, we are confident in our ability to drive continued value for our customers, employees and shareholders. Finally, I would like to thank my colleagues for their outstanding contributions during the year and all our stakeholders for your trust.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Stockholm</span>, <span data-v-02ca9be7=\"\">February 5, 2025</span></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Nico Delvaux</span><br data-v-02ca9be7=\"\"/>President and CEO</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Further information can be obtained from:<br data-v-43363f62=\"\"/></strong><span data-v-02ca9be7=\"\">Nico Delvaux</span>,<br data-v-02ca9be7=\"\"/>President and CEO, tel. no: +46 8 506 485 82<br data-v-02ca9be7=\"\"/><br data-v-02ca9be7=\"\"/>Erik Pieder,<br data-v-02ca9be7=\"\"/>Executive Vice President and CFO, tel.no: +46 8 506 485 72<br data-v-02ca9be7=\"\"/><br data-v-02ca9be7=\"\"/>Björn Tibell,<br data-v-02ca9be7=\"\"/>Head of Investor Relations, tel. no: +46 70 275 67 68<br data-v-02ca9be7=\"\"/>e-mail: <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"mailto:bjorn.tibell@assaabloy.com\" tabindex=\"0\">bjorn.tibell@assaabloy.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">ASSA ABLOY is holding a <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">telephone and web conference at 09.00 on <span data-v-43363f62=\"\">February 5, 2025</span></strong> which can be followed online at <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=3396980910&amp;u=https%3A%2F%2Fwww.assaabloy.com%2Fse%2Fen&amp;a=assaabloy.com%2Finvestors\" tabindex=\"0\">assaabloy.com/investors</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">It is possible to submit questions by telephone on: 08–505 100 31, +44 207 107 0613 or +1 631 570 5613</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">This information is information that ASSA ABLOY AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on <span data-v-370fea16=\"\">February 5, 2025</span>.</em></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information was brought to you by Cision <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=1220740761&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" tabindex=\"0\">http://news.cision.com</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=664758152&amp;u=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fr%2Fquarterly-report-q4-2024%2Cc4100644&amp;a=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fr%2Fquarterly-report-q4-2024%2Cc4100644\" tabindex=\"0\">https://news.cision.com/assa-abloy/r/quarterly-report-q4-2024,c4100644</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The following files are available for download:</p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=379784&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F7333%2F4100644%2F3246382.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F7333%2F4100644%2F3246382.pdf\" tabindex=\"0\">https://mb.cision.com/Main/7333/4100644/3246382.pdf</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">The full report (PDF)</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355872-1&amp;h=3484264407&amp;u=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fi%2Fassa-abloy-logo-door%2Cc3374416&amp;a=https%3A%2F%2Fnews.cision.com%2Fassa-abloy%2Fi%2Fassa-abloy-logo-door%2Cc3374416\" tabindex=\"0\">https://news.cision.com/assa-abloy/i/assa-abloy-logo-door,c3374416</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">ASSA ABLOY logo door</span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY12263&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/assa-abloy-quarterly-report-q4-2024-302368577.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/assa-abloy-quarterly-report-q4-2024-302368577.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  ASSA ABLOY</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 16:05:45",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny12263/assa-abloy-quarterly-report-q4-2024",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Harmony Gold Reports Five Deaths at Two Separate South African Mines",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Ian Walker </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Harmony Gold Mining said that five people died in two separate incidents in South Africa on Tuesday morning and that the causes of the accidents are currently under investigation. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The South African gold miner said Wednesday that two employees died following a mining incident at a development end at Doornkop Mine, in Soweto, Gauteng province. All blasting operations have been temporarily suspended at the mine, it said. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Separately a further three employees died following rock falls at Harmony's Joel Mine, near Theunissen in the Free State Province. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The company said that the relevant authorities have been kept fully informed of the incidents, adding that investigations into the incidents will be led by the Department of Mineral Resources and Energy, supported by labour representatives and mine management at each operation. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Ian Walker at ian.walker@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 05, 2025 02:35 ET (07:35 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-05 15:50:43",
            "link": "https://www.morningstar.com/news/dow-jones/202502052000/harmony-gold-reports-five-deaths-at-two-separate-south-african-mines",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "GSK Expects Further Profit Growth After Beating Market Views",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Helena Smolak </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  GSK expects its sales and profit to grow in the new year after cancer treatments lifted sales and profit ahead of analysts' expectations in the fourth quarter despite lower vaccines sales on weak demand in the U.S. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The British pharmaceutical giant said Wednesday that for 2025 it expects sales to grow 3% to 5%. It also targets core operating profit and core earnings per share to grow between 6% and 8%. Targets are at constant exchange rates. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  This compares with 2024 sales growth of 7%, core operating profit growth of 11% and core earnings per share growth of 10%. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Its fourth-quarter sales rose 4% at constant currencies to 8.12 billion pounds ($10.13 billion), above the 7.83 billion pounds that analysts had expected, according to a consensus polled by Visible Alpha. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Core operating profit, closely watched by analysts and investors, fell 10% at constant currencies to 1.43 billion pounds on lower-than-anticipated vaccine sales. Analysts had expected 1.385 billion pounds. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Its core earnings per share fell 10% at constant currencies to 23.2 pounds, above analysts' expectations of 20.6 pounds. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Helena Smolak at helena.smolak@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 05, 2025 02:43 ET (07:43 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-05 15:50:43",
            "link": "https://www.morningstar.com/news/dow-jones/202502052063/gsk-expects-further-profit-growth-after-beating-market-views",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Novo Nordisk's Wegovy Drug Sales Miss Expectations",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  By Dominic Chopping </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The Danish pharmaceutical giant said sales of Wegovy surged to 19.87 billion Danish kroner ($2.76 billion), against a Visible Alpha consensus estimate of 20.04 billion kroner. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Sales of diabetes drug Ozempic rose 12% on year to 33.85 billion kroner at constant exchange rates, with a Visible Alpha consensus estimate looking for 33.34 billion kroner. </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  The sales performance comes after Eli Lilly, the company's biggest competitor in the booming weight-loss market, presented a disappointing fourth-quarter sales forecast for its Zepbound and Mounjaro medications. The U.S. company said it had expected faster market growth of the drugs, but wholesalers hadn't boosted their stockpiles at the end of the year as it had expected them to. </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  Write to Dominic Chopping at dominic.chopping@wsj.com </p>\n<pre class=\"mdc-article-pre\" data-v-776baeb1=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">\n  February 05, 2025 02:19 ET (07:19 GMT)</p>\n\nCopyright (c) 2025 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2025-02-05 15:30:47",
            "link": "https://www.morningstar.com/news/dow-jones/202502051835/novo-nordisks-wegovy-drug-sales-miss-expectations",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Sobi publishes Q4 2024 report: A solid ending to a strong year",
            "description": "<div class=\"mdc-article-body\">\n\n\n\n\n\nSobi publishes Q4 2024 report: A solid ending to a strong year\n\n\n\n\n\n<span>\n<h2 class=\"mdc-article-heading\" data-v-2dc4c42a=\"\">Sobi publishes Q4 2024 report: A solid ending to a strong year</h2>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">STOCKHOLM, Feb. 5, 2025</p></span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">STOCKHOLM</span></span>, <span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Feb. 5, 2025</span></span> /PRNewswire/ -- <strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Swedish Orphan Biovitrum AB (publ) (Sobi<span data-v-43363f62=\"\">®</span>) today announced its report for the fourth quarter 2024.</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Fourth Quarter 2024</strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Total revenue increased 9 per cent, 8 per cent at constant exchange rates, (CER)<span data-v-6f730619=\"\">1</span>, to <span data-v-6f730619=\"\">SEK 7,436 M</span> (6,844)</li><li data-v-6f730619=\"\">Haematology revenue increased 22 per cent at CER to <span data-v-6f730619=\"\">SEK 4,487 M</span> (3,640), mainly driven by strong sales of Doptelet<span data-v-6f730619=\"\">® </span>of <span data-v-6f730619=\"\">SEK 1,147 M</span> (727), Vonjo<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 416 M</span> (322), Aspaveli<span data-v-6f730619=\"\">®</span>/Empaveli<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 269 M</span> (186) and launch sales of Altuvoct<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 302 M</span> (2)</li><li data-v-6f730619=\"\">Immunology revenue decreased 12 per cent at CER to <span data-v-6f730619=\"\">SEK 2,564 M</span> (2,905), explained by low Synagis<span data-v-6f730619=\"\">®</span> sales of <span data-v-6f730619=\"\">68 M</span> (897), partially offset by Beyfortus<span data-v-6f730619=\"\">®</span> royalty of <span data-v-6f730619=\"\">SEK 1,207 M</span> (890) and sales of Kineret<span data-v-6f730619=\"\">®</span> of <span data-v-6f730619=\"\">SEK 777 M</span> (621)</li><li data-v-6f730619=\"\">Revenue from the strategic portfolio<span data-v-6f730619=\"\">1*</span> grew by 50 per cent at CER to <span data-v-6f730619=\"\">SEK 4,099 M</span> (2,722)</li><li data-v-6f730619=\"\">The adjusted EBITA margin<span data-v-6f730619=\"\">1,2</span> was 34 per <span data-v-6f730619=\"\">cent (38)</span>, excluding items affecting comparability (IAC)<span data-v-6f730619=\"\">2</span>. EBITA was <span data-v-6f730619=\"\">SEK 2,572 M</span> (2,502), corresponding to a margin of 35 per <span data-v-6f730619=\"\">cent (37)</span>. EBIT was <span data-v-6f730619=\"\">SEK 1,662 M</span> (1,610)</li><li data-v-6f730619=\"\">Earnings per share (EPS) before dilution was <span data-v-6f730619=\"\">SEK 4.07</span> (3.02). Adjusted EPS before dilution<span data-v-6f730619=\"\">1</span> was <span data-v-6f730619=\"\">SEK 4.03</span> (3.21). Cash flow from operating activities was <span data-v-6f730619=\"\">SEK 1,797 M</span> (1,073)</li><li data-v-6f730619=\"\"><span data-v-6f730619=\"\">David Meek</span> was elected as a new member, and as Chair of the Board of Directors</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Full Year 2024 </strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Total revenue increased 18 per cent, 19 per cent at CER to <span data-v-6f730619=\"\">SEK 26,027 M</span> (22,123). Haematology grew 24 per cent at CER and Immunology grew 11 per cent at CER</li><li data-v-6f730619=\"\">The adjusted EBITA margin<span data-v-6f730619=\"\">1,2</span> was 36 per <span data-v-6f730619=\"\">cent (34)</span>, excluding IAC<span data-v-6f730619=\"\">2</span></li><li data-v-6f730619=\"\">The board of directors proposes that no dividend is paid for the 2024 financial year</li></ul><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Outlook 2025 </strong></p>\n<ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-6f730619=\"\"><li data-v-6f730619=\"\">Revenue is anticipated to grow by a high single-digit percentage at CER</li><li data-v-6f730619=\"\">The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue</li></ul><span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">1.</span> Alternative Performance Measures (APMs).</span></p>\n</td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">2.</span> Items affecting comparability (IAC).</span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">* The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant<span data-v-02ca9be7=\"\">®</span>, Vonjo and Zynlonta<span data-v-02ca9be7=\"\">®</span>, and royalty on Sanofi's sales of Altuviiio<span data-v-02ca9be7=\"\">®</span> and Beyfortus.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Investors, analysts, and the media are invited to a conference call on the same day at <span data-v-02ca9be7=\"\">14:30 CET</span>, <span data-v-02ca9be7=\"\">13:30 GMT</span>, and <span data-v-02ca9be7=\"\">08:30 EST</span>. The call will include a presentation of the results and a Q&amp;A session.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The presentation can be followed live <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2865459923&amp;u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3DJ7Y4u1Ji&amp;a=here\" tabindex=\"0\">here</a> or afterwards on <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2395758797&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen&amp;a=sobi.com\" tabindex=\"0\">sobi.com</a>. The slides will be made available on <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2395758797&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen&amp;a=sobi.com\" tabindex=\"0\">sobi.com</a> before the conference call.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">To participate in the conference call, please use the following dial-in details:</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Sweden</span>: +46 8 5051 0031<br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">United Kingdom</span>: +44 207 107 06 13<br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">United States</span>: +1 631 570 56 13</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">For other countries, please find the details <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=3357748000&amp;u=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fservices3.choruscall.ch%252FNUMBERS%252FAttended_Dial_In_Numbers.pdf%26data%3D05%257C02%257Cssantamaria%2540choruscall.com%257Cc46caccf82394f1c8ffd08dc369c2a22%257Cb33d8fee5ac94ed69e4d5ad041ecfd21%257C0%257C0%257C638445292073810488%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C0%257C%257C%257C%26sdata%3DTVLldmPZmSnOWKSwGGe2CdG1TlgV7dEF2ypcHkkECNE%253D%26reserved%3D0&amp;a=here\" tabindex=\"0\">here</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Sobi</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">Sobi<span data-v-02ca9be7=\"\">®</span> is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across <span data-v-02ca9be7=\"\">Europe</span>, <span data-v-02ca9be7=\"\">North America</span>, the <span data-v-02ca9be7=\"\">Middle East</span>, <span data-v-02ca9be7=\"\">Asia</span> and <span data-v-02ca9be7=\"\">Australia</span>. In 2024, revenue amounted to <span data-v-02ca9be7=\"\">SEK 26 billion</span>. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2395758797&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen&amp;a=sobi.com\" tabindex=\"0\">sobi.com</a> and <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2560329666&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsobi%2F&amp;a=LinkedIn\" tabindex=\"0\">LinkedIn</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><strong class=\"mdc-article-strong\" data-v-43363f62=\"\">Contacts</strong></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">For details on how to contact the Sobi Investor Relations Team, please click <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2060125289&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fir-contacts&amp;a=here\" tabindex=\"0\">here</a>. For Sobi Media contacts, click <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=693482582&amp;u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fmedia&amp;a=here\" tabindex=\"0\">here</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on <span data-v-02ca9be7=\"\">05 February 2025</span> at <span data-v-02ca9be7=\"\">8:00 CET</span>.</p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Gerard Tobin</span><br data-v-02ca9be7=\"\"/><span data-v-02ca9be7=\"\">Head of Investor Relations</span></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">This information was brought to you by Cision <a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=2303580505&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" tabindex=\"0\">http://news.cision.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=1025089076&amp;u=https%3A%2F%2Fnews.cision.com%2Fswedish-orphan-biovitrum-ab%2Fr%2Fsobi-publishes-q4-2024-report--a-solid-ending-to-a-strong-year%2Cc4100452&amp;a=https%3A%2F%2Fnews.cision.com%2Fswedish-orphan-biovitrum-ab%2Fr%2Fsobi-publishes-q4-2024-report--a-solid-ending-to-a-strong-year%2Cc4100452\" tabindex=\"0\">https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q4-2024-report--a-solid-ending-to-a-strong-year,c4100452</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">The following files are available for download:</p>\n<span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\"><a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=4355873-1&amp;h=1204790555&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F14266%2F4100452%2F3245896.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F14266%2F4100452%2F3245896.pdf\" tabindex=\"0\">https://mb.cision.com/Main/14266/4100452/3245896.pdf</a></span></p>\n</td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span data-v-02ca9be7=\"\">Q4 and FY 2024 report. A solid ending to a strong year</span></p>\n</td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"> </p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\"><span class=\"mdc-article-image\" data-v-91967a64=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-91967a64=\"\"><source sizes=\"(max-width: 768w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 1092w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 3x\"><source sizes=\"(max-width: 600w)\" srcset=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 1x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 2x,https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05 3x\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://c212.net/c/img/favicon.png?sn=NY12264&amp;sd=2025-02-05\"/></source></source></source></picture></span> View original content:<a class=\"mdc-link mds-link mdc-link--body\" data-v-4234e9e2=\"\" href=\"https://www.prnewswire.com/news-releases/sobi-publishes-q4-2024-report-a-solid-ending-to-a-strong-year-302368539.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/sobi-publishes-q4-2024-report-a-solid-ending-to-a-strong-year-302368539.html</a></p>\n<p class=\"mdc-article-paragraph\" data-v-02ca9be7=\"\">SOURCE  Swedish Orphan Biovitrum AB</p>\n</span>\n</div>",
            "pub_date": "2025-02-05 15:30:46",
            "link": "https://www.morningstar.com/news/pr-newswire/20250205ny12264/sobi-publishes-q4-2024-report-a-solid-ending-to-a-strong-year",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        }
    ]
}